UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
DC 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the
Securities
Exchange Act of 1934
Date of
Report (Date of earliest event reported): December 31,
2008
MEDASORB
TECHNOLOGIES CORPORATION
(Exact
name of registrant as specified in its charter)
Nevada
|
|
000-51038
|
|
98-0373793
|
(State
or other jurisdiction of incorporation)
|
|
(Commission
File Number)
|
|
(I.R.S.
Employer Identification
Number)
|
7
Deer Park Drive, Suite K, Monmouth Junction, New Jersey 08852
(Address
of principal executive office) (Zip Code)
(732)
329-8885
Registrant’s
telephone number, including area code:
Check the
appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions (see General Instruction A.2.below):
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
|
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
|
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))
|
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13c-4(c))
|
Item
5.02.
|
Departure
of Directors or Principal Officers; Election of Directors; Appointment of
Certain Officers; Compensatory Arrangements of Certain
Officers.
|
Pursuant
to a letter dated October 22, 2008, Al Kraus has resigned from his position as
President and Chief Executive Officer of MedaSorb Technologies Corporation (the
“Company”), effective December 31, 2008. He will, however, remain as
a member of the Board of Directors of our company. Mr. Kraus’ resignation was
not the result of any disagreement with the Company or any officers or directors
of the Company.
Effective
upon Mr. Kraus’ resignation, Dr. Phillip Chan, M.D., Ph.D. has been appointed
the interim Chief Executive Officer.
Phillip Chan, M.D., Ph.D.,
Interim Chief Executive Officer and Director
Dr. Chan
is a current MedaSorb Board Director. He is a Board-certified
Internal Medicine physician, trained at the Beth Israel Deaconess Medical Center
at Harvard, and received his M.D. and Ph.D. from Yale University Medical
School. As of the date of this filing, there has not been any
material plan, contract or arrangement (whether or not written) to which Dr.
Chan is a party in connection with this appointment as a director and an officer
of this Company. The Company expects to finalize such an agreement with Dr.
Chan, shortly.
Effective
December 31, 2008, Dr. James Winchester has resigned as Chief Medical Officer of
the Company. Dr. Winchester’s departure was not the result of any
disagreement with the Company or any officers or directors of the
Company. The Company is in discussions with an individual to replace
Dr. Winchester as our Chief Medical Officer, however, as of the date of this
filing, no definitive agreement has been entered into.
Effective
December 31, 2008, Mr. William Miller stepped down as Chairman of the Board of
Directors of the Company. Mr. Miller’s departure was not the result
of any disagreement with the Company or any officers or directors of the
Company. The Company is in discussions with an individual to replace
Mr. Miller as our Chairman of the Board of Directors, however, as of the date of
this filing, no definitive agreement has been entered into.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the Registrant has
duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
Date:
January 7, 2009
|
|
|
|
MEDASORB
TECHNOLOGIES CORPORATION
|
|
|
|
|
By:
|
/s/ David
Lamadrid
|
|
David
Lamadrid,
|
|
Chief
Financial Officer
|